Stay updated on Pembrolizumab Neoadjuvant in HCC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Neoadjuvant in HCC Clinical Trial page.

Latest updates to the Pembrolizumab Neoadjuvant in HCC Clinical Trial page
- CheckyesterdayChange DetectedThe page’s revision/version number was updated from v3.5.2 to v3.5.3. This indicates a site build or metadata update without changing the underlying study information presented.SummaryDifference0.1%

- Check8 days agoChange DetectedSystem revision updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check16 days agoNo Change Detected
- Check38 days agoChange Detected- Added the disease term 'Hepatocellular carcinoma' and a new resource link to the Genetic and Rare Diseases Information Center. - Updated the site revision from v3.4.3 to v3.5.0.SummaryDifference0.2%

- Check45 days agoChange DetectedRevision tag updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check73 days agoChange DetectedAdded Revision: v3.4.2 and removed the government funding lapse notice and Revision: v3.4.1.SummaryDifference0.5%

- Check80 days agoChange DetectedA government funding/operating status notice was added, with links to cc.nih.gov and opm.gov, and the site revision was updated from v3.4.0 to v3.4.1.SummaryDifference0.5%

Stay in the know with updates to Pembrolizumab Neoadjuvant in HCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Neoadjuvant in HCC Clinical Trial page.